Drug intelligence / Profile preview

AZD2939

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**AZD2939** is an investigational bispecific antibody that concurrently targets TIGIT and PD-1, designed to enhance anti-tumor immune responses by blocking both checkpoints. Developed by AstraZeneca with the TIGIT-binding component derived from Compugen's COM902 program under an exclusive license agreement, it is being evaluated for its potential in cancer immunotherapy. The TIGIT arm originates from computational target discovery efforts focused on novel immuno-oncology pathways.

Targets

PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)

Beyond the preview

Go deeper on AZD2939.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD2939.

Explore the full profile